Requests that the FDA to revoke the approval of, or require the reformulation of, all New Drug Applications (NDAs) and Abbreviated New Drug Applications (ANDAs) for rectal suppository formulations of indomethacin that contain the excipient butylated hydroxytoluene.
🏛 Food and Drug Administration (FDA)FDA-2025-P-7377
Documents
7
Total comments
0
all analyzed
Comment status
Closed
Last activity
—
In this docket
Documents
Rules, notices, and supporting material — the primary rule pinned first.
No documents mirrored for this docket yet.